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Abstract
Background: Currently, there is no evidence on the combination of lamivudine and thymosin
alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of
lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the
treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B patients.
Results: We searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese
Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the
Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.
Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination
treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate
(80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg
seroconversion rate (45.1% vs. 15.2%, P < 0.00001).
Conclusion:  Among HBeAg-positive patients, thymosin alpha-1 and lamivudine combination
therapy may be more effective than lamivudine monotherapy, providing superior rates of
biochemical response, virological response, and HBeAg seroconversion.
Background
Hepatitis B is an infectious disease caused by hepatitis B
virus (HBV) that affects more than 400 million people
worldwide [1-4]. Chronic HBV infection is a serious prob-
lem associated with cirrhosis and hepatocellular carci-
noma [5], which are becoming more prevalent
worldwide, especially in Asia where the virus is often
transmitted from mother to child at birth [6]. Chronic
hepatitis B (CHB) infection is a dynamic state of interac-
tions between the virus, host hepatocytes, and the host
immune response. Immunological studies have found
that impaired HBV-specific T cell reactivity is a major rea-
son for the development of chronic infection. The HBV
cytotoxic T lymphocyte response in patients with chronic
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HBV infection is generally weak or totally undetectable.
The treatment for CHB consists of individualized, single-
agent therapy with interferon or nucleoside analogues.
Interferon, an immunomodulating agent, is effective in
clearing the virus but is associated with adverse effects.
Nucleoside analogues, such as lamivudine, can control
HBV infection but have drug-resistant strains of HBV are
increasingly prevalent [7]. They are effective in the therapy
of chronic HBV infection but the efficacy is far from satis-
factory. Persistent HBV infection represents a clear unmet
need for improved antiviral therapeutic modalities.
Recently, some interesting data have recently emerged
concerning the use of thymosin alpha-1 (T1) as mono-
therapy for CHB [8]. T1 is a 28-amino acid polypeptide
produced synthetically but originally isolated from thy-
mosin fraction 5, a bovine thymus extract containing a
number of immunologically active peptides [9]. In vitro
studies have shown that T1 can influence T-cell produc-
tion and maturation and stimulate production of Th1
cytokines such as interferon-gamma and interleukin-2,
and activate natural killer cell-mediated cytotoxicity
[10,11]. It is an immunomodulatory agent that is able to
augment some specific T lymphocyte functions, particu-
larly ones that promote the T helper 1 cell responses
involved in host antiviral defense [12].
Meta-analysis of 4 randomized controlled studies investi-
gating the safety and efficacy of T1 monotherapy for the
treatment of chronic hepatitis B showed that six months
treatment of T1 (1.6 mg 2/week) almost doubled the
sustained response rate compared with controls [13].
Monotherapy with lamivudine, interferon, or T1 is
unlikely to be sufficient for the eradication of a CHB infec-
tion. Only a few randomized controlled clinical trials
have been conducted to evaluate the efficacy of the com-
bination of lamivudine and T1 in CHB. These trials were
usually small, and their results were controversial. No
meta-analysis on lamivudine versus lamivudine and T1
for treating CHB has been reported. Here we provide a
comparison of lamivudine monotherapy to the combina-
tion of lamivudine and T1 in the treatment of hepatitis
B e antigen (HBeAg)-positive patients.
Results
Studies identified
A total of 154 studies were identified by the searches. By
scanning titles and abstracts, 105 redundant publications,
reviews, case reports and meta-analyses were excluded.
After referring to full texts, 41 studies that did not satisfy
the inclusion criteria were removed from consideration.
Eight studies were left for analysis which involved 583
patients, of whom 288 were included in monotherapy
groups and 295 were included in combination therapy
groups. Among them, 3 studies were published in English
(Lee 2008 [14], Wu 2002[15], available by searching the
database of PUBMED; Lin 2003[16], available by search-
ing the database of The Cochrane Central Register of Con-
trolled Trials); the others were published in Chinese, only
by searching the database of CNKI [17-21]. We did not
search citations in languages other than Chinese or Eng-
lish. Human trials were mostly in China because of the
high prevalence of CHB in China, and thus results were
mostly published in Chinese journals.
Table 1 shows the characteristics of the eight trials
included in the meta-analysis. All had clearly stated inclu-
sion and exclusion criteria. In addition, all studied popu-
lations with comparable baseline characteristics between
the combination therapy and monotherapy groups,
including age, sex, biochemical, and serological parame-
ters. Four of the eight trials reported data for 12 months.
All eight studies were randomized. Four studies men-
tioned withdrawal rates; however, none of the trials was
blinded, and none mentioned the concealment of alloca-
tion clearly in the randomization process. Accordingly, we
considered four studies as category B, and four as category
C.
Table 1: Description of included randomized controlled trials
Author Sample size (C/M) Therapy period Virological end-point Follow-up period(m) Study design Grade
Lee 2008 62(31/31) T1 24w+LAM 52w HBV DNA(-) 0 RCT B
Li 2005 68(34/34) T1 52w+LAM 52w HBV DNA(-) 0 RCT C
Liang 2006 72(36/36) T1 6m+LAM 12m HBV DNA(-) 12 RCT B
Lin 2003 72(35/37) T1 26w+LAM 52w HBV DNA(-) 12 RCT B
Liu 2005 98(49/49) T1 26w+LAM52w HBV DNA(-) 0 RCT C
Sun 2008 81(41/40) T1 6m+LAM12m HBV DNA(-) 12 RCT C
Wu 2002 60(29/31) T1 6m+LAM12m HBV DNA(-) 12 RCT B
Zhao 2007 68(33/35) T1 6m+LAM12-18m HBV DNA(-) 0 RCT C
Abbreviations C: combination therapy; M: monotherapy; T1: thymosin alpha 1; LAM: lamivudine; w: weeks; m: months; RCT: randomized 
controlled trail.Virology Journal 2009, 6:63 http://www.virologyj.com/content/6/1/63
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Biochemical response
The biochemical parameters at the end of the treatment
are shown in Figure 1. The results of the eight studies
showed normalization rates for ALT in the combination
therapy group as 80.2%, compared to 68.8% in the mon-
otherapy group at the end of treatment. No statistical het-
erogeneity was detected (2 = 10.02, df = 7, P = 0.19, I2 =
30.2%), allowing the use of a fixed effect model for meta-
analysis. The difference of biochemical response rates at
the end of treatment significantly favored the combina-
tion of T1 and lamivudine over lamivudine alone (RR
1.16, 95% CI 1.04–1.30, Z = 2.56, P = 0.01) (Figure 1).
The biochemical response of the patients in four studies at
the end of 12 months' follow-up is shown in Figure 2.
These included 285 patients and showed the biochemical
response rates of ALT of the combination therapy group
was 70.2%, compared to a 34.0% rate in the monotherapy
group; no statistical heterogeneity (2 = 1.98, df = 3, P =
0.58, I2 = 0%) was found. The difference in biochemical
response rates at the end of 12 months' follow-up reached
statistical significance (RR 5.38, 95% CI 3.13–9.25, Z =
6.10, P < 0.00001) (Figure 2). Compared to lamivudine
monotherapy, combination therapy with T1 and lami-
vudine was more effective in terms of biochemical
response.
Virological response
The virological response at the end of the treatment is
shown in Figure 3. The results of the eight studies showed
the virological response rate of the combination therapy
group was 84.7%, while the monotherapy group rate was
74.9%. There was no statistical heterogeneity (2 = 10.65,
df = 7, P = 0.15, I2 = 34.3%), allowing use of the fixed
effect model for meta-analysis. The difference of the viro-
logical response rates at the end of treatment between the
two groups achieved statistical significance (RR 1.14, 95%
CI 1.05–1.23, Z = 3.17, P = 0.002) (Figure 3).
The virological response at the end of 12 months follow-
up is shown in Figure 4. The results of the four studies
(285 patients) showed the virological response rate for the
combination therapy group was 68.0%, while the mono-
therapy group response rate was 55.5% (Figure 4); no sta-
tistical heterogeneity was noted (2 = 0.94, df = 3, P = 0.82,
I2 = 0%). The difference of virological response rates at the
end of 12 months follow-up between the two groups was
statistically significant (RR 1.74, 95% CI 1.07–2.84, Z =
2.21, P = 0.03) (Figure 4). When compared to lamivudine
Analysis of the normalization rate of ALT at the end of the treatment between lamivudine and thymosin versus lamivudine  groups Figure 1
Analysis of the normalization rate of ALT at the end of the treatment between lamivudine and thymosin ver-
sus lamivudine groups.Virology Journal 2009, 6:63 http://www.virologyj.com/content/6/1/63
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Analysis of the normalization rate of ALT at the end of 12 months follow-up between lamivudine and thymosin versus lamivu- dine groups Figure 2
Analysis of the normalization rate of ALT at the end of 12 months follow-up between lamivudine and thymosin 
versus lamivudine groups.
Analysis of the virological response at the end of the treatment between lamivudine and thymosin versus lamivudine groups Figure 3
Analysis of the virological response at the end of the treatment between lamivudine and thymosin versus lam-
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monotherapy, combination therapy with T1 and lami-
vudine was more effective as measured by virological
response.
Seroconversion of HBeAg to HBeAb
The seroconversion of HBeAg to HBeAb at the end of the
treatment is shown in Figure 5. The seroconversion rate of
patients receiving combination therapy was 45.1%, while
the monotherapy group was 15.2% at the end of treat-
ment. No statistical heterogeneity was found (2 = 11.04,
df = 7, P = 0.14, I2 = 36.6%), allowing the use of a fixed
effect model for meta-analysis. The difference of serocon-
version rates at the end of treatment between the two
groups achieved statistical significance (RR 2.98, 95% CI
2.22–4.01, Z = 7.28, P < 0.00001) (Figure 5). Therefore, in
comparison to lamivudine monotherapy, combination
therapy with T1 and lamivudine is more effective on
seroconversion of HBeAg.
The seroconversion of HBeAg to HBeAb at the end of 12
months follow-up is shown in Figure 6. Four studies
(which included 285 patients) showed the seroconversion
rate of HBeAg for the combination therapy group as
41.1%, while the monotherapy group rate was 10.4% at
the end of 12 months follow-up. No statistical heteroge-
neity (2 = 2.94, df = 3, P = 0.40, I2 = 0%). The difference
in seroconversion rates at the end of treatment between
the two groups achieved statistical significance (RR 5.91,
95% CI 3.15–11.10, Z = 5.53, P < 0.00001) (Figure 6). In
comparison to lamivudine monotherapy, combination
therapy with T1 and lamivudine was more effective with
respect to seroconversion of HBeAg.
Adverse events
No serious adverse events were reported in either group,
and no biochemical abnormalities were reported in these
studies. Patients reported nonspecific symptoms such as
fatigue, mild dizziness, low fever, alopecia, and local dis-
comfort at the injection site in the combination therapy
group.
Discussion
Meta-analysis is a statistical technique for assembling the
results of several independently conducted but closely
related studies to arrive at a single numerical estimate of
risk or benefit. The suboptimal outcomes of current hepa-
titis B monotherapies have prompted the notion of com-
bination therapy to achieve a synergistic effect [2]. In the
present study, we considered HBeAg-positive patients,
who tend to have more active disease and are at higher
risk for complications. We evaluated combination therapy
of T1 and lamivudine for CHB patients, pooling data
from all pertinent randomized-controlled trials. If suc-
cessful, this meta-analysis will help reach evidence-based
conclusions, resolve the controversy surrounding this
topic, and direct further investigation.
Analysis of the virological response at the end of 12 months follow-up between lamivudine and thymosin versus lamivudine  groups Figure 4
Analysis of the virological response at the end of 12 months follow-up between lamivudine and thymosin ver-
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Analysis of the HBeAg seroconversion rate at the end of 12 months follow-up between lamivudine and thymosin versus lami- vudine groups Figure 6
Analysis of the HBeAg seroconversion rate at the end of 12 months follow-up between lamivudine and thy-
mosin versus lamivudine groups.
Analysis of the HBeAg seroconversion rate at the end of the treatment between lamivudine and thymosin versus lamivudine  groups Figure 5
Analysis of the HBeAg seroconversion rate at the end of the treatment between lamivudine and thymosin ver-
sus lamivudine groups.Virology Journal 2009, 6:63 http://www.virologyj.com/content/6/1/63
Page 7 of 9
(page number not for citation purposes)
In this analysis, it appears that the combination of T1
(1.6 mg subcutaneously, twice a week) for a minimum of
24 weeks and lamivudine (100 mg orally, daily) for a
minimum of 52 weeks was more effective than lamivu-
dine monotherapy at the end of treatment. The combina-
tion therapy provided superior rates of sustained
virological response (P = 0.01), biochemical response (P
= 0.002), and HBeAg seroconversion (P < 0.00001) than
did monotherapy. Further, combination therapy may
improve the rates of ALT normalization (P < 0.00001),
HBV DNA loss (P = 0.03), and HBeAg seroconversion (P
< 0.00001) at the end of 12 months' follow-up.
In general, the objectivity and accuracy of meta-analysis
rely on the availability of high-quality studies. We should
consider results of the current analysis cautiously for sev-
eral reasons. Firstly, blinding of subjects and clinicians
was difficult because the combination therapy group
received injected T1 and orally administered lamivudine
while the monotherapy group only received orally admin-
istered lamivudine. As a result, none of the studies
included in the analysis was double-blinded; however, it
is unlikely that the lack of blinding could affect the out-
comes assessed. In such a study design, blinding could be
achieved only if both the combination therapy group and
monotherapy group received oral and injected trial medi-
cations (i.e., the monotherapy group could receive pla-
cebo injection). Secondly, none of the trials described the
method used to generate the allocation sequence. Despite
these potential sources of bias, randomization was ade-
quate in the eight trials as shown by the baseline equiva-
lency of experimental groups. Finally, HBV DNA was
measured using a hybridization assay in one trial (Lee,
2008), and HBV DNA was measured by polymerase chain
reaction in the other trials. The different HBV DNA assays
used in the different trials may also have caused addi-
tional variability in the sensitivity of HBV DNA detection
and thus in the estimate of efficacy. Additional issues
include publication bias, small trial sizes, and a high rate
of studies that were conducted in China. In other coun-
tries, the efficacy and safety of T1 and lamivudine versus
lamivudine for treating CHB have not been largely
explored, potentially resulting in language bias.
Conclusion
In summary, thymosin alpha-1 and lamivudine combina-
tion therapy may be more effective than lamivudine mon-
otherapy among HBeAg-positive patients, providing
superior rates of biochemical response, virological
response, and HBeAg seroconversion. And more high-
quality, well-designed, randomized controlled trials that
are adequately powered are clearly needed to guide evolv-
ing standards of care for CHB. Randomization procedures
should be clearly described, allocation concealment
should be emphasized, and the approaches should be
reported. Blinding should be conducted, though this may
be difficult.
Methods
Inclusion criteria
For inclusion in our analysis, studies were required to
meet several criteria. First, the study population must be
18–75 years of age and diagnosed with HBeAg-positive
CHB, with HBV DNA positivity lasting for at least 6
months, and must show elevated alanine transaminase
(ALT) levels. Gender and ethnic origin were not consid-
ered. Second, trials must have been described as rand-
omized Third, the intervention(s) must have included
lamivudine monotherapy and combination therapy with
lamivudine and T1. Monotherapy with lamivudine (100
mg orally, daily) must have been for at least of 52 weeks,
and combination therapy must have been with lamivu-
dine (100 mg orally, daily) for at least 52 weeks and T1
(1.6 mg subcutaneously, twice a week) for at least 24
weeks. Fourth, published data must include biochemical
and virological response rates, seroconversion rates
(HBeAg to HBeAb), and adverse effects.
Exclusion criteria
Trials were excluded if they did not meet the inclusion cri-
teria above. Animal or in vitro studies were also excluded,
as were review articles, duplicate or redundant publica-
tions, and letters to the editor. Studies involving patients
with antibodies to human immunodeficiency virus (HIV),
hepatitis C virus (HCV), hepatitis D virus (HDV) or hepa-
titis E virus (HEV), studies of patients with decompen-
sated liver disease, evidence of other forms of liver disease,
or a history of malignancy were also excluded.
Search strategy
Retrieval of trials published up to September, 2008 was
performed through PUBMED (from 1966 onwards),
EMBASE (from 1966), CBMdisk (Chinese Biomedical
Database, from 1978), and CNKI (National Knowledge
Infrastructure, from 1980). The Cochrane Central Register
of Controlled Trials and the Cochrane Database of Sys-
tematic Reviews were also searched. The search process
was designed to find initially all trials involving terms:
"Hepatitis B", "e antigen positive", "thymalfasin", "thy-
mosin alpha-1" "lamivudine", "randomized controlled
trial", "randomization", "controlled study", "multicenter
study", "double blind procedure", "single blind proce-
dure" (and multiple synonyms for each term). Computer
searches were supplemented with a manual search. Search
results were downloaded to a reference database and fur-
ther screened.
Definition of main outcomes
Published data at the start and the end of the therapy
include the efficacy measure, i.e. biochemical and virolog-Virology Journal 2009, 6:63 http://www.virologyj.com/content/6/1/63
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ical response rates, seroconversion rates (HBeAg to
HBeAb), and adverse effects. Biochemical response was
defined as normalization of ALT levels. Virological
response was defined as attainment of undetectable (or
below 1000 copies/mL) levels of HBV DNA, as deter-
mined by polymerase chain reaction or measured using a
hybridization assay. The serum HBV markers were
detected by the Enzyme-Linked Immunosorbent Assay.
We analyzed the outcomes at the end of the active treat-
ment phase.
Methods of review
Data extraction
Two reviewers independently selected the trials and per-
formed the data extraction. Discrepancies were resolved
by discussion among reviewers. In some cases, original
principal investigators were contacted to collect informa-
tion that was collected but not published.
Quality assessment
The overall quality of each study was assessed in accord-
ance with the Cochrane format [22], using a grading
scheme for each of four main aspects, each classified into
three grades (A, B, and C) as follows: 1) quality of rand-
omization, 2) quality of allocation concealment, 3) qual-
ity of blinding, and 4) quality of the description of
withdrawals and dropouts. The grades were: A) adequate,
with correct procedures, B) unclear, without a description
of methods, and C) inadequate procedures, methods, or
information. Based on these four criteria, the studies
could be divided into three groups. "A" studies had a low
risk of bias for studies and were scored with A grades for
all items; "B" studies had a moderate risk of bias for stud-
ies with one or more B grades; "C" studies had a high risk
of bias and were those with one or more C grades.
Statistical methods
Statistical analysis was carried out using Review Manager
(version 4.2) provided by The Cochrane Collaboration.
Dichotomous data were presented as relative risk (RR)
and continuous outcomes as weighted mean difference
(WMD), both with 95% confidence intervals (CI). The
overall effect was tested using Z scores, with significance
being set at P < 0.05. Meta-analysis was performed using
fixed-effect or random-effect methods, depending on
absence or presence of significant heterogeneity [23]. Sta-
tistical heterogeneity between trials was evaluated by the
chi-squared and I square (I2) tests, with significance being
set at P < 0.10. In the absence of statistically significant
heterogeneity, the fixed-effect method was used to com-
bine the results. When heterogeneity was confirmed (P =
0.10), the random-effect method was used.
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